Pfizer's Lyrica proves positive for fibromyalgia; Keddem garners $15M for small molecule modulators; Can a Tibetan mushroom treat asthma?;

Conversations on Twitter :

 @FierceBiotech: From Cmed expanding in North Carolina as CRO-tech combos take off. Story | Follow @FierceBiotech

 @JohnCFierce: SR One, etc., provide $37.5M round for Applied Genetic Technologies. Working on gene therapies. News | Follow @JohnCFierce

 @RyanMFierce: Cmed expanding in North Carolina as CRO-tech combos take off. Report | Follow @RyanMFierce

> Pfizer ($PFE) says that a Phase III study for Lyrica produced promising evidence of efficacy against fibromyalgia. The condition afflicts some 5 million people in the U.S. Release

> The Baltimore Sun provides an upbeat assessment of MedImmune, noting a big increase in pipeline projects in the years since AstraZeneca ($AZN) bought out the company for $15 billion. Report

> Compugen subsidiary Keddem Bioscience has raised $15 million to back its work on small molecule modulators. Story

Pharma News

@FiercePharma: Pfizer CEO Ian Read ordered to testify in Chantix case. More | Follow @FiercePharma

> Novo Norkdisk, largest Nordic company, shoots for top drugmaker. Report

> Calpers, others, battle Pfizer separately on Bextra shareholder claims. News

> Illumina gets dose of its own medicine, spurned by Complete Gemomics. Item

Medical Device News

 @FierceMedDev: Wright Medical plans to merge with BioMimetic in a $380M deal: orthopedics + regenerative medicine = the future. More | Follow @FierceMedDev

 @MarkHFierce: St. Jude gained a CE mark for its new transcatheter aortic heart valve/transfemoral delivery system. Watch out, Sapien? News | Follow @MarkHFierce

 @DamianFierce: Big week for CRO Chiromics, signing deals with GSK and Bristol-Myers. Story | Follow @DamianFierce

> GE Healthcare slashes jobs in Vermont. Item

> Wright to grab BioMimetic in $190 million-plus agreement. Story

> HeartSine hit with Class I over defibrillator recall. News

> St. Jude Medical wins CE mark for TAVI tech. Article

Biotech IT News

> Merck backs Remedy Informatics with $6M investment. Report

> Roche engages patient groups in social media effort. Article

> Johnson & Johnson, Merck and Eli Lilly to rip red tape from clinical trials. Story

CRO News

> PPD gets high-tech for adaptive trials. Item

> Big Pharma supergroup plots clinical trial site database. Story

> Chiromics inks discovery deals with Bristol-Myers, GSK. Article

> Aptuit extends GSK partnership at Italian site. More

> WuXi ticks up income after strong Q3. Report

And Finally… Investigators in the U.K. say that a rare Tibetan mushroom could provide a new compound that could be used to treat asthma. The same compound is already being investigated as a potential cancer therapy as well. Story


Suggested Articles

The discovery that 500 cancers can be slotted into 10 subtypes, each of which is driven by a common set of proteins, could inspire new therapies.

Can an unexpected Sarepta win be good news for Biogen?

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.